1Professor of Medicine, The Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University , Chicago, Illinois
2Multiple Myeloma Program, Division of Hematology/Oncology, The Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
Hypergammaglobulinemia increases serum viscosity and is the most common cause of hyperviscosity syndrome. Monoclonal hypergammaglobulinemia resulting in hyperviscosity syndrome is seen in multiple myeloma and Waldenström's macroglobulinemia. The reasons for elevated viscosity are increased protein content and large molecular size, abnormal polymerization, and abnormal shape of immunoglobulin molecules. Other hematologic and metabolic abnormalities seen in patients with plasma cell dyscrasias also contribute to hyperviscosity. Symptomatic hyperviscosity is much more common in Waldenström's macroglobulinemia (10 to 30%) than it is in myeloma (2 to 6%). Symptoms of hyperviscosity usually appear when the normal serum viscosity of 1.4 to 1.8 cp reaches 4 to 5 cp, corresponding to a serum immunoglobulin M (IgM) level of at least 3 g/dL, an IgG level of 4 g/dL, and an IgA level of 6 g/dL. Symptoms of hyperviscosity include constitutional symptoms; bleeding; and ocular, neurological, and cardiovascular manifestations. Immediate therapy of symptomatic hyperviscosity is directed at reduction of blood viscosity by plasmapheresis to control symptoms. Long-term management is directed at control of the underlying disease to prevent production of the monoclonal protein. There may be a small proportion of individuals, usually old or with severely compromised performance status, who undergo plasma exchange as the sole symptomatic therapy of hyperviscosity secondary to plasma cell dyscrasia.
2
Rosenson R S, McCormick A, Uretz E F.
Distribution of blood viscosity values and biochemical correlates in healthy adults.
Clin Chem .
1996;
42
1189-1195
7
Roberts-Thomson P J, Mason D Y, MacLennan I C.
Relationship between paraprotein polymerization and clinical features in IgA myeloma.
Br J Haematol .
1976;
33
117-130
8
Mestecky J, Hammack W J, Kulhavy R, Wright G P, Tomana M.
Properties of IgA myeloma proteins isolated from sera of patients with the hyperviscosity syndrome.
J Lab Clin Med .
1977;
89
919-927
10
Chandy K G, Stockley R A, Leonard R C. et al .
Relationship between serum viscosity and intravascular IgA polymer concentration in IgA myeloma.
Clin Exp Immunol .
1981;
46
653-661
12
Hall C G, Abraham G N.
Size, shape, and hydration of a self-associating human IgG myeloma protein: axial asymmetry as a contributing factor in serum hyperviscosity.
Arch Biochem Biophys .
1984;
233
330-337
13
Joles J A, Willekes-Koolschijn N, Koomans H A.
Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine.
Kidney Int .
1997;
52
761-770
19
Singh A, Eckardt K U, Zimmermann A. et al .
Increased plasma viscosity as a reason for inappropriate erythropoietin formation.
J Clin Invest .
1993;
91
251-256
20
Russell J A, Powles R L.
The relationship between serum viscosity, hypervolaemia and clinical manifestations associated with circulating paraprotein.
Br J Haematol .
1978;
39
163-175
25
Reinhart W H, Lutolf O, Nydegger U R, Mahler F, Straub P W.
Plasmapheresis for hyperviscosity syndrome in macroglobulinemia Waldenström and multiple myeloma: influence on blood rheology and the microcirculation.
J Lab Clin Med .
1992;
119
69-76
29
Garcia-Sanz R, Montoto S, Torrequebrada A. et al .
Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.
Br J Haematol .
2001;
115
575-582
30
Kyrtsonis M C, Vassilakopoulos T P, Angelopoulou M K. et al .
Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit (Erratum: Ann Hematol 2002;81:124).
Ann Hematol .
2001;
80
722-727
32
Facon T, Brouillard M, Duhamel A. et al .
Prognostic factors in Waldenström's macroglobulinemia: a report of 167 cases.
J Clin Oncol .
1993;
11
1553-1558
35
Hoffkes H G, Heemann U W, Teschendorf C, Uppenkamp M, Philipp T.
Hyperviscosity syndrome: efficacy and comparison of plasma exchange by plasma separation and cascade filtration in patients with immunocytoma of Waldenström's type.
Clin Nephrol .
1995;
43
335-338
36
Zucchelli P, Pasquali S, Cagnoli L, Ferrari G.
Controlled plasma exchange trial in acute renal failure due to multiple myeloma.
Kidney Int .
1988;
33
1175-1180
